Cash, cash equivalents, and deposits as of December 31, 2025 totaled $54M, with no debt. Updated revenue guidance projects $24-26M in 2026, $32-35M in 2027, and $50-55M in 2028. All guidance periods assume continued support from BARDA and the U.S. Department of Defense. The 2028 outlook also assumes a potential initial contribution related to EscharEx, subject to regulatory approval.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDWD:
- MediWound reports clinical data on NexoBrid’s effectiveness
- MediWound: Strong Financial Health and Market Opportunities Drive Buy Rating
- MediWound price target raised to $36 from $31 at H.C. Wainwright
- MediWound’s Q3 2025: Growth and Strategic Advances
- Mediwound’s Strong Q3 Performance and Strategic Advancements Justify Buy Rating